Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2013
Exchange: NASDAQ
Website: epizyme.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2022 | $1.50 | Outperform → Market Perform | Cowen |
| 6/27/2022 | Outperform → Neutral | Wedbush | |
| 3/2/2022 | $15.00 → $10.00 | Buy | HC Wainwright & Co. |
| 8/10/2021 | $10.00 → $5.00 | Equal-Weight → Underweight | Morgan Stanley |
| 8/10/2021 | $36.00 → $15.00 | Buy | HC Wainwright & Co. |